Evidence map›Paper›PMID 34951957›Full record

ArticleCancer cell2022

Reuterin in the healthy gut microbiome suppresses colorectal cancer growth through altering redox balance.

Hannah N Bell, Ryan J Rebernick, Joshua Goyert, Rashi Singhal, Miljan Kuljanin, Samuel A Kerk, Wesley Huang, Nupur K Das, Anthony Andren, Sumeet Solanki and 7 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer cell, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 166 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
166citing papers in PubMed, 1 pooled it
14.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

166 citing papers in PubMed, 1 synthesis or guideline pooled it, 271 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Biosynthetic reuterin improved the intestinal health in pigs.Animal nutrition (Zhongguo xu mu shou yi xue hui) · 2026
    Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

106 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 1 country.

Hannah N BellDepartment of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, MI 48109, USA.
Ryan J RebernickDepartment of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI 48109, USA.
Joshua GoyertDepartment of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, MI 48109, USA.
Rashi SinghalDepartment of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, MI 48109, USA.
Miljan KuljaninDepartment of Cell Biology, Harvard Medical School, Boston, MA 02115, USA; Division of Radiation and Genome Stability, Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
Samuel A KerkDepartment of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, MI 48109, USA.
Wesley HuangDepartment of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, MI 48109, USA.
Nupur K DasDepartment of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, MI 48109, USA.
Anthony AndrenDepartment of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, MI 48109, USA.
Sumeet SolankiDepartment of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, MI 48109, USA.
Shannon L MillerDepartment of Neurology, University of Michigan, Ann Arbor, MI 48109, USA; Cellular and Molecular Biology Graduate Program, University of Michigan, Ann Arbor, MI 48109, USA.
Peter K ToddDepartment of Neurology, University of Michigan, Ann Arbor, MI 48109, USA; VA Ann Arbor HealthCare System, Ann Arbor, MI 48109, USA.
Eric R FearonDepartment of Pathology, University of Michigan, Ann Arbor, MI 48109, USA; Department of Human Genetics, University of Michigan, Ann Arbor, MI 48109, USA; University of Michigan Rogel Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA; Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA.
Costas A LyssiotisDepartment of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, MI 48109, USA; University of Michigan Rogel Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA; Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA.
Steven P GygiDepartment of Cell Biology, Harvard Medical School, Boston, MA 02115, USA.
Joseph D ManciasDivision of Radiation and Genome Stability, Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
Yatrik M ShahDepartment of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, MI 48109, USA; University of Michigan Rogel Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA; Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA. Electronic address: shahy@umich.edu.
University of Michigan · USDana-Farber Cancer Institute · USHarvard University · USVA Ann Arbor Healthcare System · US

Funding

XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Alexey I Nesvizhskii · 1988 to 2026
$178.2M
MICHIGAN MEDICAL SCIENTIST TRAINING PROGRAMT32GM007863 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI COLLINS, KATHLEEN L. · 1985 to 2024
$38.3M
University of Michigan Center for Gastrointestinal ResearchP30DK034933 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI OMARY, BISHR · 1986 to 2021
$22.5M
Pilot and Feasibility (P and F) ProgramP30DK089503 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Kanakadurga Singer · 2010 to 2026
$20.3M
CELLULAR AND MOLECULAR BIOLOGY AT MICHIGANT32GM007315 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI PUTHENVEEDU, MANOJKUMAR A · 1985 to 2021
$12.8M
Translational Research in GI CancerP50CA130810 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BRENNER, DEAN E. · 2010 to 2016
$11.8M
Statistics and Bioinformatics Core - WangU24DK097153 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BURANT, CHARLES F · 2012 to 2017
$10.1M
The FMR1 CGG repeat as functional element and therapeutic target in Fragile X associated disordersP50HD104463 · NICHD · BAYLOR COLLEGE OF MEDICINE · PI NELSON, DAVID LOREN, TODD, PETER K · 2020 to 2024
$9.0M
Control of iron absorption by intestinal HIF2 in iron and hematological disordersR01DK095201 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SHAH, YATRIK M · 2012 to 2025
$5.7M
The role of HIF2alpha in colon carcinogenesisR01CA148828 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SHAH, YATRIK M · 2010 to 2025
$5.2M
Hexanucleotide repeat translation in ALS and Frontotemporal DementiaR01NS099280 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Peter K Todd · 2016 to 2026
$4.9M
Targeting cysteine import to induce ferroptotic cell death in pancreatic cancerR01CA215607 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Kenneth P. Olive · 2017 to 2026
$4.0M
BLRD VA I01 BX004842NCI NIH HHS F30 CA257292NCI NIH HHS F31 CA247457NCI NIH HHS F99 CA264414NCI NIH HHS P30 CA046592NCI NIH HHS P50 CA130810NCI NIH HHS R01 CA148828NCI NIH HHS R01 CA215607NCI NIH HHS R01 CA244931NCI NIH HHS R01 CA245546NCI NIH HHS R01 CA248160NCI NIH HHS R37 CA237421NICHD NIH HHS P50 HD104463NIDDK NIH HHS P30 DK034933NIDDK NIH HHS P30 DK089503NIDDK NIH HHS R01 DK095201NIDDK NIH HHS U24 DK097153NIGMS NIH HHS T32 GM007315NIGMS NIH HHS T32 GM007863NINDS NIH HHS F31 NS127371NINDS NIH HHS R01 NS099280
6 · The paper itself

Abstract

Microbial dysbiosis is a colorectal cancer (CRC) hallmark and contributes to inflammation, tumor growth, and therapy response. Gut microbes signal via metabolites, but how the metabolites impact CRC is largely unknown. We interrogated fecal metabolites associated with mouse models of colon tumorigenesis with varying mutational load. We find that microbial metabolites from healthy mice or humans are growth-repressive, and this response is attenuated in mice and patients with CRC. Microbial profiling reveals that Lactobacillus reuteri and its metabolite, reuterin, are downregulated in mouse and human CRC. Reuterin alters redox balance, and reduces proliferation and survival in colon cancer cells. Reuterin induces selective protein oxidation and inhibits ribosomal biogenesis and protein translation. Exogenous Lactobacillus reuteri restricts colon tumor growth, increases tumor reactive oxygen species, and decreases protein translation in vivo. Our findings indicate that a healthy microbiome and specifically, Lactobacillus reuteri, is protective against CRC through microbial metabolite exchange.

Indexed as

Gastrointestinal MicrobiomeOxidation-ReductionAnimalsBiomarkersCell Line, TumorCell ProliferationColorectal NeoplasmsDisease Models, AnimalEnergy MetabolismGlutathioneGlyceraldehydeHost Microbial InteractionsHumansIntestinal MucosaMetabolomicsMetagenomics3-hydroxypropionaldehydeBiomarkersGlutathioneGlyceraldehydePropanecolorectal cancerLactobacillus reuterimetabolitesMicrobiomeprotein oxidationReuterin

Identifiers

PMID34951957
PMCPMC8847337
OpenAlexW4200155765

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.